Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle

Biochemical and Biophysical Research Communications

Volumn 329, Issue 3, 2005, Pages 1067-1075

  Sirvent, Pascal ^a,b   Mercier, Jacques ^b   Vassort, Guy ^a   Lacampagne, Alain ^a  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Calcium; Hypercholesterolemia; Mitochondria; Myotoxicity; Sarcoplasmic reticulum; Skeletal muscle; Sparks; Statins

Indexed keywords

CYCLOPIAZONIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SIMVASTATIN;

ADULT; AMPLITUDE MODULATION; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CYTOPLASM; DEPOLARIZATION; DRUG EFFECT; EXERCISE TOLERANCE; HUMAN; HUMAN TISSUE; MALE; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; MUSCLE CRAMP; MUSCLE DYSREGULATION; MUSCLE FATIGUE; MUSCLE MITOCHONDRION; MUSCLE TOXICITY; MYALGIA; NORMAL HUMAN; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM; SIDE EFFECT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SODIUM CALCIUM EXCHANGE;

EID: 14844327531     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.02.070     Document Type: Article

References (41)

1. S.M. Grundy HMG-CoA reductase inhibitors for treatment of hypercholesterolemia N. Engl. J. Med. 319 1988 24 33
2. M. Takemoto, K. Node, H. Nakagami, Y. Liao, M. Grimm, Y. Takemoto, M. Kitakaze, and J.K. Liao Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy J. Clin. Invest. 108 2001 1429 1437
3. J.K. Liao Isoprenoids as mediators of the biological effects of statins J. Clin. Invest. 110 2002 285 288
4. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, L. Brown, J.W. Warnica, J.M. Arnold, C.C. Wun, B.R. Davis, and E. Braunwald The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators N. Engl. J. Med. 335 1996 1001 1009
5. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339 (1998) 1349-1357
6. M. Ucar, T. Mjorndal, and R. Dahlqvist HMG-CoA reductase inhibitors and myotoxicity Drug Saf 22 2000 441 457
7. G. Ghirlanda, A. Oradei, A. Manto, S. Lippa, L. Uccioli, S. Caputo, A.V. Greco, and G.P. Littarru Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study J. Clin. Pharmacol. 33 1993 226 229
8. R. Laaksonen, K. Jokelainen, T. Sahi, M.J. Tikkanen, and J.J. Himberg Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans Clin. Pharmacol. Ther. 57 1995 62 66
9. T. Mutoh, T. Kumano, H. Nakagawa, and M. Kuriyama Involvement of tyrosine phosphorylation in HMG-CoA reductase inhibitor-induced cell death in L6 myoblasts FEBS Lett. 444 1999 85 89
10. 2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors Biochem. Biophys. Res. Commun. 202 1994 1579 1585
11. S. Pierno, A. De Luca, A. Liantonio, C. Camerino, and D. Conte Camerino Effects of HMG-CoA reductase inhibitors on excitation-contraction coupling of rat skeletal muscle Eur. J. Pharmacol. 364 1999 43 48
12. 2+-releasing effect of cerivastatin on the sarcoplasmic reticulum of mouse and rat skeletal muscle fibers J. Pharmacol. Sci. 93 2003 279 288
13. C.W. Ward, S. Reiken, A.R. Marks, I. Marty, G. Vassort, and A. Lacampagne Defects in ryanodine receptor calcium release in skeletal muscle from post-myocardial infarct rats FASEB J. 17 2003 1517 1519
14. M. Jakobisiak, S. Bruno, J.S. Skierski, and Z. Darzynkiewicz Cell cycle-specific effects of lovastatin Proc. Natl. Acad. Sci. USA 88 1991 3628 3632
15. U. Laufs, H. Kilter, C. Konkol, S. Wassmann, M. Bohm, and G. Nickenig Impact of HMG CoA reductase inhibition on small GTPases in the heart Cardiovasc. Res. 53 2002 911 920
16. 2+] in frog skeletal muscle J. Gen. Physiol. 111 1998 207 224
17. M.R. Duchen Contributions of mitochondria to animal physiology: from homeostatic sensor to calcium signalling and cell death J. Physiol. 516 Pt 1 1999 1 17
18. M. Crompton, S. Virji, V. Doyle, N. Johnson, and J.M. Ward The mitochondrial permeability transition pore Biochem. Soc. Symp. 66 1999 167 179
19. M.A. Matlib, J.D. Doane, N. Sperelakis, and F. Riccippo-Neto Clonazepam and diltiazem both inhibit sodium-calcium exchange of mitochondria, but only diltiazem inhibits the slow action potentials of cardiac muscles Biochem. Biophys. Res. Commun. 128 1985 290 296
20. W. Droge Free radicals in the physiological control of cell function Physiol. Rev. 82 2002 47 95
21. A. Ceriello, and E. Motz Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited Arterioscler. Thromb. Vasc. Biol. 24 2004 816 823
22. S. Delbosc, J.P. Cristol, B. Descomps, A. Mimran, and B. Jover Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress Hypertension 40 2002 142 147
23. H. Nakagami, K.S. Jensen, and J.K. Liao A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms Ann Med 35 2003 398 403
24. S. Sugiyama HMG CoA reductase inhibitor accelerates aging effect on diaphragm mitochondrial respiratory function in rats Biochem. Mol. Biol. Int. 46 1998 923 931
25. K. Satoh, and K. Ichihara Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischemic rat hearts Eur. J. Pharmacol. 292 1995 271 275
26. A.K. Goli, S.A. Goli, R.P. Byrd Jr., and T.M. Roy Simvastatin-induced lactic acidosis: a rare adverse reaction Clin. Pharmacol. Ther. 72 2002 461 464
27. D. Hudman, R.D. Rainbow, C.L. Lawrence, and N.B. Standen The origin of calcium overload in rat cardiac myocytes following metabolic inhibition with 2,4-dinitrophenol J. Mol. Cell. Cardiol. 34 2002 859 871
28. W. Irwin, E. Fontaine, L. Agnolucci, D. Penzo, R. Betto, S. Bortolotto, C. Reggiani, G. Salviati, and P. Bernardi Bupivacaine myotoxicity is mediated by mitochondria J. Biol. Chem. 277 2002 12221 12227
29. 2+ in mammalian and amphibian muscle. An RyR isoform-specific role in excitation-contraction coupling? J. Gen. Physiol. 124 2004 409 428
30. 2+ steps produced by rapid solution exchange Biophys. J. 71 1996 732 741
31. 2+ release channels (ryanodine receptors) Science 281 1998 818 821
32. 2+ spark frequency in ventricular myocytes Am. J. Physiol. 272 1997 H657 H668
33. P.D. Thompson, P. Clarkson, and R.H. Karas Statin-associated myopathy JAMA 289 2003 1681 1690
34. T. Kantola, K.T. Kivisto, and P.J. Neuvonen Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations Clin. Pharmacol. Ther. 64 1998 177 182
35. U. Laufs, V. La Fata, J. Plutzky, and J.K. Liao Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors Circulation 97 1998 1129 1135
36. J.J. Lilja, K.T. Kivisto, and P.J. Neuvonen Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors Clin. Pharmacol. Ther. 64 1998 477 483
37. J.Y. Luh, B.M. Karnath, Issues in statin-associated myopathy, Jama 290 (2003) 888; author reply 888-889
38. J.T. Backman, C. Kyrklund, K.T. Kivisto, J.S. Wang, and P.J. Neuvonen Plasma concentrations of active simvastatin acid are increased by gemfibrozil Clin. Pharmacol. Ther. 68 2000 122 129
39. O. Mousa, D.C. Brater, K.J. Sunblad, and S.D. Hall The interaction of diltiazem with simvastatin Clin. Pharmacol. Ther. 67 2000 267 274
40. K. Nagasawa, K. Nagai, A. Ishimoto, and S. Fujimoto Transport mechanism for lovastatin acid in bovine kidney NBL-1 cells: kinetic evidences imply involvement of monocarboxylate transporter 4 Int. J. Pharm. 262 2003 63 73
41. H. Dubouchaud, G.E. Butterfield, E.E. Wolfel, B.C. Bergman, and G.A. Brooks Endurance training, expression, and physiology of LDH, MCT1, and MCT4 in human skeletal muscle Am. J. Physiol. Endocrinol. Metab. 278 2000 E571 E579